Effects of Atrasentan on Kidney Gene Transcription, Mesangial Cell Proliferation, and Proteinuria in Immunoglobulin A Nephropathy
The acute mechanistic effects of atrasentan demonstrated in vitro and in vivo support the therapeutic potential of atrasentan in IgAN. The ongoing AFFINITY and ASSIST phase 2 trials, and the ALIGN phase 3 trial in patients with IgAN will further evaluate the translation of these mechanistic effects to the clinical efficacy and safety of atrasentan.
Authors
- Chi-hsuan Nieh
- Jay J. Kuo (ORCID: https://orcid.org/0000-0001-8741-2638)
- Jayakumar Surendradoss (ORCID: https://orcid.org/0000-0002-4777-1756)
- Toshiki Kano
- Nathan A. Naidu
- Jeff Lester
- N. Eric Olson
- Mark T. McConnell
- Jennifer H. Cox
- Joyce Wu
- Yusuke Suzuki
- Marvin G. Gunawan
Institutions
- Juntendo University (JP)
- Nova Research Company (United States) (US)
- Novartis (Canada) (CA)
Publication Details
- Journal
- Kidney360
- Published
- 2025-12-24
- DOI
- https://doi.org/10.34067/kid.0000001000
- Primary Topic
- Renal Diseases and Glomerulopathies
- Type
- article
- Field-Weighted Citation Impact
- 0.00